Compare HAIN & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HAIN | MAIA |
|---|---|---|
| Founded | 1993 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.1M | 77.1M |
| IPO Year | 1996 | 2022 |
| Metric | HAIN | MAIA |
|---|---|---|
| Price | $0.65 | $1.30 |
| Analyst Decision | Hold | |
| Analyst Count | 9 | 0 |
| Target Price | ★ $2.23 | N/A |
| AVG Volume (30 Days) | ★ 1.1M | 632.8K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,457,769,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.55 | $0.87 |
| 52 Week High | $3.07 | $3.19 |
| Indicator | HAIN | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 37.32 | 45.52 |
| Support Level | $0.59 | $1.26 |
| Resistance Level | $0.73 | $1.50 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 23.40 | 39.66 |
The Hain Celestial Group Inc is a health and wellness company. It makes natural and organic food and personal-care products. The company offers products across various categories such as snacks, baby & kids food, beverages, meal preparation, and personal care through brands like Garden Veggie Snacks, Terra chips, Garden of Eatin snacks, Hartley's Jelly, and Celestial Seasonings teas, among others. It operates under two reportable segments: North America and International. The majority of its revenue is derived from the North America segment, which represents the sale of its products in the United States and Canada. The International segment includes the sale of its products in the United Kingdom and the Western European region.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of targeted immunotherapies for cancer, with an initial focus on non-small cell lung cancer (NSCLC), which represents the majority of lung cancer cases. Its asset, ateganosine (THIO, also known as 6-thio-dG or 6-thio-deoxyguanosine), is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The treatment approach involves administering THIO followed by the immune checkpoint inhibitor Libtayo (cemiplimab), which is manufactured and commercialized by Regeneron.